Picture supply: Getty Pictures
The Various Funding Market (AIM) doesn’t have the perfect popularity. In addition to containing a whole lot of unprofitable companies which might be extra prone to fold than broaden, AIM shares might be very risky. Nevertheless, I believe there are at the least a couple of diamonds within the tough to contemplate shopping for.
Tanking share worth
Bioventix (LSE: BVXP) is arguably one instance. Shares within the developer and industrial provider of monoclonal antibodies have tumbled over 40% within the final 12 months. Whereas a few of that is doubtless the results of broader market issues, quite a bit is unquestionably right down to the corporate overstating revenues by £327,000 because of a buyer error. In actuality, the agency’s precise revenues got here in under market expectations.
This information has clearly shaken confidence and pushed the inventory right down to a multi-year low.
Nevertheless, I reckon this may very well be a good time to consider loading up. As worrying as latest type has been, that is nonetheless an organization that reeks of high quality. Margins and returns on capital stay sky-high, thanks partially to having only a few staff. Whereas this has led to the shares buying and selling at a premium to the broader market, the present price-to-earnings (P/E) ratio of 16 is already considerably decrease than the agency’s five-year common of 27.
Half-year numbers — due on 24 March — will likely be value studying. I reckon it would take solely a small chink of sunshine to get the shares transferring in the precise course once more.
Gross sales down
One other area of interest AIM-listed firm to contemplate that’s been battered is laser-guided tools producer Somero Enterprises (LSE: SOM). Its share worth has fallen practically 20% in 2025 already.
So what’s gone fallacious right here? Properly, buyers have change into more and more involved concerning the normal financial outlook, significantly within the US (the place the corporate’s based mostly) which makes up three-quarters of gross sales. There’s an opportunity that issues will go from dangerous to worse if rates of interest keep larger for longer and drive purchasers to delay buying the corporate’s cement-levelling tech.
Like Bioventix nevertheless, that is one other small-cap that scores constantly nicely on high quality metrics. Supported by a robust stability sheet and really skilled administration, Somero can also be a market chief in what it does. Though by no means assured, the dividend yield at the moment stands at a meaty 6.8% too.
Monster dividend yield
A remaining AIM inventory that’s value pondering is base metals producer Central Asia Metals (LSE: CAML). Like the opposite two talked about right here, its shares have fallen in latest occasions, down 14% or so within the final 12 months.
Once more, a lot of this seems to be the results of normal geopolitical issues. That stated, demand for lead has been decrease. The corporate drills for this (and zinc) at its mine in North Macedonia. It additionally has copper operations in Kazakhstan.
On a extra constructive word, the shares now yield an unimaginable 10% for FY25. Fairly whether or not buyers will see all of this money is open to debate if prices proceed to rise. Nevertheless, the overall dividend is anticipated to be lined by revenue as issues stand. The inventory appears to be like very low-cost too, altering fingers at a P/E of simply seven for FY25.
Full-year numbers are due tomorrow (20 March). Will probably be attention-grabbing to see how present holders react.
Picture supply: Getty Pictures
The Various Funding Market (AIM) doesn’t have the perfect popularity. In addition to containing a whole lot of unprofitable companies which might be extra prone to fold than broaden, AIM shares might be very risky. Nevertheless, I believe there are at the least a couple of diamonds within the tough to contemplate shopping for.
Tanking share worth
Bioventix (LSE: BVXP) is arguably one instance. Shares within the developer and industrial provider of monoclonal antibodies have tumbled over 40% within the final 12 months. Whereas a few of that is doubtless the results of broader market issues, quite a bit is unquestionably right down to the corporate overstating revenues by £327,000 because of a buyer error. In actuality, the agency’s precise revenues got here in under market expectations.
This information has clearly shaken confidence and pushed the inventory right down to a multi-year low.
Nevertheless, I reckon this may very well be a good time to consider loading up. As worrying as latest type has been, that is nonetheless an organization that reeks of high quality. Margins and returns on capital stay sky-high, thanks partially to having only a few staff. Whereas this has led to the shares buying and selling at a premium to the broader market, the present price-to-earnings (P/E) ratio of 16 is already considerably decrease than the agency’s five-year common of 27.
Half-year numbers — due on 24 March — will likely be value studying. I reckon it would take solely a small chink of sunshine to get the shares transferring in the precise course once more.
Gross sales down
One other area of interest AIM-listed firm to contemplate that’s been battered is laser-guided tools producer Somero Enterprises (LSE: SOM). Its share worth has fallen practically 20% in 2025 already.
So what’s gone fallacious right here? Properly, buyers have change into more and more involved concerning the normal financial outlook, significantly within the US (the place the corporate’s based mostly) which makes up three-quarters of gross sales. There’s an opportunity that issues will go from dangerous to worse if rates of interest keep larger for longer and drive purchasers to delay buying the corporate’s cement-levelling tech.
Like Bioventix nevertheless, that is one other small-cap that scores constantly nicely on high quality metrics. Supported by a robust stability sheet and really skilled administration, Somero can also be a market chief in what it does. Though by no means assured, the dividend yield at the moment stands at a meaty 6.8% too.
Monster dividend yield
A remaining AIM inventory that’s value pondering is base metals producer Central Asia Metals (LSE: CAML). Like the opposite two talked about right here, its shares have fallen in latest occasions, down 14% or so within the final 12 months.
Once more, a lot of this seems to be the results of normal geopolitical issues. That stated, demand for lead has been decrease. The corporate drills for this (and zinc) at its mine in North Macedonia. It additionally has copper operations in Kazakhstan.
On a extra constructive word, the shares now yield an unimaginable 10% for FY25. Fairly whether or not buyers will see all of this money is open to debate if prices proceed to rise. Nevertheless, the overall dividend is anticipated to be lined by revenue as issues stand. The inventory appears to be like very low-cost too, altering fingers at a P/E of simply seven for FY25.
Full-year numbers are due tomorrow (20 March). Will probably be attention-grabbing to see how present holders react.
